Another PD-(L)1 combination has bitten the dust. This time, Syndax Pharmaceuticals’ HDAC inhibitor entinostat failed in trials with Roche’s Tecentriq and Pfizer/Merck KGaA’s Bavencio, in triple-negative breast cancer and ovarian cancer respectively. Syndax has postponed all work with entinostat plus checkpoint inhibitors, including a planned pivotal trial with Keytruda in non-small cell lung cancer. The company will await overall survival data from an NCI-sponsored trial of entinostat plus the aromatase inhibitor exemestane in breast cancer before making further decisions on the entinostat/PD-(L)1 combinations. This has effectively shifted Syndax's entire R&D focus to the phase I project SNDX-6352, which is being tested alone in graft-versus-host disease, and as monotherapy and in combination with Astrazeneca's Imfinzi in solid tumours; and the preclinical asset SNDX-5613, for which Syndax plans to submit an IND application in the second quarter of 2019. The group’s shares tumbled 11% post-market yesterday.
|Entinostat’s clinical programme grinds to a halt|
|Encore 601||Keytruda combo||NSCLC and melanoma cohorts being presented at AACR; colorectal cancer cohort shelved||NCT02437136|
|Encore 602||Tecentriq combo||Previously treated, PD-1-naive triple-negative breast cancer – failed||NCT02708680|
|Encore 603||Bavencio combo||Heavily pretreated advanced epithelial ovarian cancer – failed||NCT02915523|
|Encore 607||Keytruda combo||NSCLC patients who have progressed on Keytruda + chemo – deferred||n/a|
|E2112*||exemestane combo||HR+, Her2- breast cancer – interim analysis due in Q2 2019||NCT02115282|
|*Sponsored by the NCI. Sources: Syndax, clinicaltrials.gov.|